Clinical Trials Logo
  1. Home
  2. Anlotinib
  3. NCT04757779

A Single-arm, Phase Ⅱ Clinical Trial of Anlotinib Hydrochloride Combined With Irinotecan or Docetaxel for Second Line Treatment of Nonsensitive Relapsed Small-cell Lung Cancer

Anlotinib Clinical Trial

Official title:
A Single-arm, Phase Ⅱ Clinical Trial of Anlotinib Hydrochloride Combined With Irinotecan or Docetaxel for Second Line Treatment of Nonsensitive Relapsed Small-cell Lung Cancer

Clinical Trial Summary

Anlotinib hydrochloride is a multi-target antiangiogenic drug. It was recommended by Chinese Society of Clinical Oncology(CSCO) guideline as a third-line treatment for advanced small-cell lung cancer. This study intends to assess the efficacy and safety of anlotinib hydrochloride combined with irinotecan or docetaxel for second line treatment of nonsensitive relapsed small-cell lung cancer.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04757779
Study type Interventional
Source First People's Hospital of Hangzhou
Contact Bing Xia, MD
Phone 86 571 56006388
Email bxia_hzch@hotmail.com
Status Recruiting
Phase Phase 2
Start date December 30, 2019
Completion date December 30, 2024
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06048315 - A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody Phase 3
Recruiting NCT04116918 - Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC
Recruiting NCT04566952 - Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Phase 2
Not yet recruiting NCT05030077 - Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma Phase 2
Recruiting NCT05602415 - Anlotinib and Radiotherapy in Resectable Soft Tissue Sarcoma Phase 2
Withdrawn NCT04620473 - Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer Phase 2
Recruiting NCT04803851 - Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer Phase 1/Phase 2
Recruiting NCT05167994 - Preoperative IMRT With Concurrent Anlotinib for Localised Extremity or Trunk Sarcoma Phase 2
Recruiting NCT04684017 - Anlotinib Plus Etoposide and Carboplatin as First-line Treatment for Extensive-stage Small Cell Lung Cancer Phase 2
Not yet recruiting NCT04665609 - Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCC Phase 3
Not yet recruiting NCT05778149 - Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation Phase 2
Recruiting NCT05311579 - Niraparib Plus Anlotinib for Recurrent Ovarian Cancer Phase 2
Not yet recruiting NCT04797507 - SHR-1210 in Combination With Anlotinib in Patients With Advanced or Metastatic Esophageal Squamous Cell Cancer Phase 2
Active, not recruiting NCT05400070 - Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC Phase 2
Not yet recruiting NCT04807166 - Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer Phase 2
Completed NCT04271813 - Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC) Phase 2
Completed NCT04002284 - Anlotinib in Metastatic HER2 Negative Breast Cancer Phase 2
Recruiting NCT04278222 - Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric or Gastro-esophageal Junction Cancer (APICAL-GE) Phase 2
Active, not recruiting NCT02072031 - Phase II Study of Anlotinib Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma（RCC） Phase 2
Not yet recruiting NCT03589950 - Anlotinib Plus Chemotherapy for Patients With Advanced Non-small Cell Lung Cancer Phase 2